-- €50,000 award goes to University Hospital of Lille in France to fund research into the
potential impact of Extracorporeal Photopheresis (ECP) on fibrosing
processes --
DUBLIN, Aug. 31, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global
biopharmaceutical company, today announced the recipient of 2020's
Advancing Extracorporeal Photopheresis (ECP) Immunomodulation
Investigator Award. The winning entry was submitted by Professor
David Launay of the University
Hospital of Lille in France.
The winning entry will evaluate the impact of immunomodulatory
intervention on the development of fibrosing processes in an
experimental model that could underpin the efficacy of ECP
immunomodulation on immune-mediated inflammatory diseases (IMIDs).
Among chronic diseases, IMIDs represent a common cause of fibrosis,
a hardening or scarring of tissue, and the end result of many
chronic inflammatory reactions. Fibrosis carries a high
morbi-mortality rate, and a lack of effective therapies to prevent
or reverse fibrosis presents a major issue for
clinicians.1
Prof. Launay is based at the Department of Internal Medicine and
Clinical Immunology at the University Hospital of Lille, the France-National Reference Center
for Systemic and Autoimmune Diseases and part of the European
Reference Network ReCONNECT and also works at the Institute for
Translational Research in Inflammation (Infinite – U1286 Inserm |
Univ. Lille | CHU Lille) in
Lille.
Along with the 2020 Investigator Award, Prof. Launay's team will
receive an educational grant of €50,000 to support their research.
"I am excited to receive this award and look forward to sharing the
results of important research into an innovative intervention to
address a challenging medical condition," said Prof.
Launay.
Mallinckrodt developed the
Investigator Award in 2018 to mark 30 years of its pioneering
THERAKOS ECP Immunomodulation™ and is now in its third year. The
Investigator Award reflects the company's ongoing commitment to the
science of immunomodulation through ECP and its therapeutic
applications. The award recognizes individuals and institutions
whose research contributes to the advancement of knowledge in this
area of medicine.
Prof. Launay's winning submission follows 2019's winner, a team
from Newcastle University in
collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation
Trust. The inaugural Investigator Award in 2018 went to Dr.
Nick Matthews and Dr. Arun Alfred of the Department of Hematology at
Rotherham NHS Foundation Trust in the United Kingdom, for their work addressing the
use of ECP in the treatment of chronic graft-versus-host disease
(GVHD).
"Mallinckrodt has pioneered ECP
immunomodulation through its THERAKOS™ CELLEX™ Photopheresis System
and is proud to support continued research that pushes an exciting
field of medicine still further. I congratulate Prof. Launay on
receiving the 2020 Investigator Award, and very much look forward
to seeing the results of his work," said Steven Romano, M.D., Executive Vice President
and Chief Scientific Officer of Mallinckrodt.
Entries were invited from clinicians and scientists working on
translational or outcomes-based research, as well as collaborative
projects. Submissions were assessed on a range of criteria,
specifically scientific merit, originality and feasibility. The
2021 Advancing ECP Immunomodulation Investigator Award will be open
for entries in September 2020. Full
details on how to enter can be found at
https://www.therakos.eu/healthcareprofessionals/thetherakos-institute/
Mallinckrodt is the world's only
provider of approved, fully-integrated systems for administering
immunomodulatory therapy through ECP. Its Therakos therapeutic
platforms, including the latest generation THERAKOS™ CELLEX™
Photopheresis System, are used by academic medical centers,
hospitals, and treatment centers in nearly 40 countries and have
delivered more than 1 million treatments globally. For more
information, please visit https://www.therakos.eu/.
For important safety information related to the THERAKOS™
CELLEX™ Photopheresis System, please visit
https://therakos.eu/?show=important-safety-information.
ABOUT MALLINCKRODT
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, nephrology,
pulmonology and ophthalmology; immunotherapy and neonatal
respiratory critical care therapies; analgesics and
gastrointestinal products. Its Specialty Generics reportable
segment includes specialty generic drugs and active pharmaceutical
ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
CONTACTS
EMEA Media Inquiries
MNKmediarelations@mnk.com
US Media Inquiries
Ron Bartlett
H+K Strategies
Senior Vice President
M: +1 813 545 2399
ron.bartlett@hkstrategies.com
Investor Relations
Daniel J. Speciale
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners. © 2020 Mallinckrodt. AU-2000009 05/20
REFERENCES
1. TA Wynn, Cellular and molecular mechanisms of fibrosis, J
Pathol 2008; 214: 199–210, https://doi.org/10.1002/path.2277, et
al.
Logo -
https://mma.prnewswire.com/media/167103/mallinckrodt_plc_logo.jpg